Ionis Pharmaceuticals (IONS)
(Real Time Quote from BATS)
$41.05 USD
-0.78 (-1.87%)
Updated Sep 24, 2024 01:28 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenue: Total commercial revenue
- 309.00
- 303.00
- 342.00
- 365.00
- --
- Revenue - Line of Business (LOBR)
- Revenue: Research and development revenue under collaborative agreements
- 479.00
- 284.00
- 468.00
- 364.00
- 771.00
- Revenue - Line of Business (LOBR)
- Revenue: Commercial Revenue: Spinraza royalties
- 240.00
- 242.00
- 268.00
- 286.58
- 292.99
- Revenue - Line of Business (LOBR)
- Revenue: Commercial Revenue: Tegsedi and Waylivra revenue, net
- 35.00
- 30.05
- 55.50
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Commercial Revenue: Licensing and royalty revenue
- 34.00
- 31.00
- 18.00
- 8.00
- 17.00
- Revenue - Line of Business (LOBR)
- Revenue: R&D Revenue: Amortization from upfront payments
- 125.00
- 69.00
- 78.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: R&D Revenue: Collaborative agreement revenue
- 353.00
- 207.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: R&D Revenue: Milestone payments
- 101.00
- 74.00
- 88.00
- --
- --